负载二氢卟吩e6的山羊奶源细胞外囊泡用于切伦科夫发光诱导的光动力治疗
本研究以山羊奶源细胞外囊泡(GEV)装载光敏剂二氢卟吩e6(Ce6)构建Ce6@GEV,利用18F-FDG产生的切伦科夫发光激活光动力效应。体外4T1细胞实验显示Ce6@GEV联合18F-FDG使细胞活力从88.02±1.30%降至23.79±1.59%;动物实验中Ce6@GEV+18F-FDG组抑瘤率58.02%、生存期35天(40%),未见重要器官损伤。
要点
- GEV可高效递送Ce6进入肿瘤细胞,联合18F-FDG产生切伦科夫发光诱导光动力杀伤。
- Ce6@GEV注射后24小时肿瘤/肝脏荧光比值峰值为1.36±0.09。
- Ce6@GEV+18F-FDG组抑瘤率58.02%,生存期35天(40%),未见重要器官损伤。
核心结论
- 18F-FDG与Ce6在肿瘤组织同时蓄积有望克服传统光动力治疗穿透不足的缺陷。
- 该策略有潜力利用靶向放射性示踪剂提供内部激发光,将光动力治疗拓展至包括转移灶在内的多种肿瘤。
- 作者期望该方法在深部实体瘤精准治疗中发挥关键作用。
研究设计与样本
- 通过差速超速离心从商品山羊奶中分离GEV,共孵育装载光敏剂Ce6获得Ce6@GEV。
- 用共聚焦显微镜和流式细胞术检测Ce6@GEV的肿瘤摄取,用流式细胞术测凋亡率、ROS监测试剂盒测1O2产生。
- 用IVIS设备检测切伦科夫辐射和切伦科夫辐射能量转移(CRET),小动物IVIS成像系统观察GEV递送系统在肿瘤中的蓄积。
- 在肿瘤部位于0.5、1、2小时行PET/CT和切伦科夫发光成像;体内抗肿瘤治疗监测六组荷瘤小鼠的肿瘤体积、生存时间和体重变化。
- 采集血液和感兴趣器官(心、肝、脾、肺、肾、肿瘤)行血液学分析、免疫组化和H&E染色。
主要发现
- 4T1细胞与Ce6@GEV孵育4小时后共聚焦显微镜见胞质内强红色荧光信号,表明GEV装载的Ce6可高效递送入肿瘤细胞。
- Ce6@GEV与18F-FDG共同孵育4T1细胞时,细胞活力从88.02±1.30%降至23.79±1.59%,显示良好的切伦科夫发光诱导光动力效应。
- 体内荧光图像显示Ce6@GEV注射后24小时肿瘤/肝脏比值峰值为1.36±0.09。
- 体内抗肿瘤治疗中Ce6@GEV+18F-FDG组抑瘤率58.02%,优于其他组,生存期最长(35天,40%)。
- 整个治疗过程中血液生化分析和组织学观察均未发现重要器官损伤,提示该治疗策略的生物安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Photodynamic therapy (PDT) is a promising cancer treatment strategy with rapid progress in preclinical and clinical settings. However, the limitations in penetration of external light and precise delivery of photosensitizers hamper its clinical translation. As such, the internal light source such as Cerenkov luminescence (CL) from decaying radioisotopes offers new opportunities. Herein, we show that goat milk-derived extracellular vesicles (GEV) can act as a carrier to deliver photosensitizer Chlorin e6 (Ce6) and tumor-avid 18F-FDG can activate CL-induced PDT for precision cancer theranostics. METHODS: GEV was isolated via differential ultracentrifugation of commercial goat milk and photosensitizer Ce6 was loaded by co-incubation to obtain Ce6@GEV. Tumor uptake of Ce6@GEV was examined using confocal microscopy and flow cytometry. To demonstrate the ability of 18F-FDG to activate photodynamic effects against cancer cells, apoptosis rates were measured using flow cytometry, and the production of 1O2 was measured by reactive oxygen species (ROS) monitoring kit. Moreover, we used the IVIS device to detect Cherenkov radiation and Cerenkov radiation energy transfer (CRET). For animal experiments, a small-animal IVIS imaging system was used to visualize the accumulation of the GEV drug delivery system in tumors. PET/CT and CL images of the tumor site were performed at 0.5, 1, and 2 h. For in vivo antitumor therapy, changes of tumor volume, survival time, and body weight in six groups of tumor-bearing mice were monitored. Furthermore, the blood sample and organs of interest (heart, liver, spleen, lungs, kidneys, and tumor) were collected for hematological analysis, immunohistochemistry, and H&E staining. RESULTS: Confocal microscopy of 4T1 cells incubated with Ce6@GEV for 4 h revealed strong red fluorescence signals in the cytoplasm, which demonstrated that Ce6 loaded in GEV could be efficiently delivered into tumor cells. When Ce6@GEV and 18F-FDG co-existed incubated with 4T1 cells, the cell viability plummeted from more than 88.02 ± 1.30% to 23.79 ± 1.59%, indicating excellent CL-induced PDT effects. In vivo fluorescence images showed a peak tumor/liver ratio of 1.36 ± 0.09 at 24 h after Ce6@GEV injection. For in vivo antitumor therapy, Ce6@GEV + 18F-FDG group had the best tumor inhibition rate (58.02%) compared with the other groups, with the longest survival rate (35 days, 40%). During the whole treatment process, neither blood biochemical analysis nor histological observation revealed vital organ damage, suggesting the biosafety of this treatment strategy. CONCLUSIONS: The simultaneous accumulation of 18F-FDG and Ce6 in tumor tissues is expected to overcome the deficiency of traditional PDT. This strategy has the potential to extend PDT to a variety of tumors, including metastases, using targeted radiotracers to provide internal excitation of light-responsive therapeutics. We expect that our method will play a critical role in precision treatment of deep solid tumors.
引用
- Guo R, Jiang D, Gai Y, et al. Chlorin e6-loaded goat milk-derived extracellular vesicles for Cerenkov luminescence-induced photodynamic therapy. Eur J Nucl Med Mol Imaging. 2022. PMID: 36222853. doi:10.1007/s00259-022-05978-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。